GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Ningbo Menovo Pharmaceutical Co 603538.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

21.17

-2.22%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ningbo Menovo Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603538.SS. It has been listed since 7 April 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.50bn and net income of CN¥102.2m. At that date it held total assets of CN¥4.85bn and shareholders' equity of CN¥2.34bn.

Ningbo Menovo Pharmaceutical Co., Ltd. engages in the research, development, testing, production, and sale of pharmaceutical products. The company is headquartered in Ningbo, Zhejiang. The company went IPO on 2017-04-07. The Company’s products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The firm distributes its products to both domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Apr 2017
Employees
2,297

Leadership

Pay as last reported

  • Mr. Chengzhi YaoChairman of the Board, General Manager, since 2018CN¥533,100
  • Mr. Gaofeng YingFinance Director, Secretary of the Board, Director, since 2019CN¥266,700
  • Mr. Jian XuDeputy General ManagerCN¥530,300
  • Ms. Fang YaoDirectorCN¥202,400
  • Ms. Hongjun BeiIndependent Director, since 2024
  • Ms. Jie WeiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Ningbo Menovo Pharmaceutical employs 2297 full-time employees in the Health Care sector.
  • The company produces gastropathic and cardiovascular medicines including anti-hypertension and anti-thrombus drugs.
  • Ningbo Menovo distributes pharmaceutical products to both domestic and overseas markets.

Weaknesses

  • Ningbo Menovo's products focus on gastropathic and cardiovascular medicine segments.
  • The company's business is limited to pharmaceutical products without diversification.
  • Ningbo Menovo has no mention of R&D investment in the provided facts.

Opportunities

  • Ningbo Menovo can expand its cardiovascular medicine segment in the Chinese market.
  • The company may grow its overseas market presence in the Health Care industry.
  • Ningbo Menovo could leverage its 2297 employees for further product development.

Threats

  • Ningbo Menovo faces competition in the Chinese pharmaceutical market.
  • The company's reliance on cardiovascular medicine may pose risks from market saturation.
  • Ningbo Menovo's limited product range could hinder growth in the Health Care sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.